FY2030 Earnings Estimate for ONCY Issued By HC Wainwright

Oncolytics Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright forecasts Oncolytics Biotech will earn $0.01 per share in FY2030 and maintains a Buy rating; the consensus estimate for the current full year is a loss of $0.29 per share.
  • Analyst opinions are mixed: MarketBeat reports a consensus Hold rating and an average $5.00 price target, based on one Buy and one Sell rating.
  • ONCY shares fell 11.3% and opened at $0.39. The company’s latest quarterly loss of $0.08 per share was wider than analysts’ expected $0.05 loss.
  • Interested in Oncolytics Biotech? Here are five stocks we like better.

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Oncolytics Biotech in a research report issued on Thursday, November 19th. HC Wainwright analyst P. Trucchio anticipates that the company will earn $0.01 per share for the year. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.29) per share.

Separately, Weiss Ratings upgraded shares of Oncolytics Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oncolytics Biotech currently has a consensus rating of "Hold" and an average target price of $5.00.

Check Out Our Latest Report on Oncolytics Biotech

Oncolytics Biotech Trading Down 11.3%

Shares of ONCY stock opened at $0.39 on Friday. Oncolytics Biotech has a 12 month low of $0.33 and a 12 month high of $1.30. The stock has a market cap of $53.18 million, a P/E ratio of -1.22 and a beta of 1.26. The company has a 50 day simple moving average of $0.54 and a two-hundred day simple moving average of $0.82.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.03).

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ONCY. Vantage Point Financial LLC purchased a new position in Oncolytics Biotech during the second quarter valued at approximately $28,000. Fifth Third Bancorp boosted its position in shares of Oncolytics Biotech by 87.9% in the third quarter. Fifth Third Bancorp now owns 85,526 shares of the company's stock worth $57,000 after purchasing an additional 40,000 shares during the period. Susquehanna International Group LLP increased its stake in shares of Oncolytics Biotech by 224.6% in the second quarter. Susquehanna International Group LLP now owns 134,129 shares of the company's stock worth $127,000 after purchasing an additional 92,806 shares in the last quarter. Connective Capital Management LLC purchased a new stake in shares of Oncolytics Biotech in the second quarter worth $176,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 129.6% during the 3rd quarter. International Assets Investment Management LLC now owns 462,008 shares of the company's stock valued at $310,000 after buying an additional 260,748 shares in the last quarter. Institutional investors own 6.82% of the company's stock.

Oncolytics Biotech Company Profile

(Get Free Report)

Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer. The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment. Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions.

Featured Stories

Earnings History and Estimates for Oncolytics Biotech (NASDAQ:ONCY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oncolytics Biotech Right Now?

Before you consider Oncolytics Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.

While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines